Moderna’s post-pandemic future was thrown into question Thursday after it disclosed multiple setbacks that disappointed investors. The biotech company has been largely shut out of the COVID ...

What Happened? Shares of biotechnology company Moderna (NASDAQ:MRNA) fell 3.6% in the morning session after JPMorgan added ...

In morning trades, Moderna stock rose nearly 4% to 28.22 ... support rapid response in a future influenza pandemic, and pave the way for COVID-19 combination vaccines," Bancel added. Notably, the ...

Moderna, already in cash-saving mode amid uncertain vaccine dynamics, is backing off from its plans to construct an mRNA drug ...

The market outlook The demand outlook for Moderna's COVID-19 vaccine is not as strong as before. 68% of the world population has received at least one dose of the COVID-19 vaccine.

These ratings convey expectations for the relative performance of Moderna compared to the broader market. Price Targets: Analysts set price targets as an estimate of a stock's future value.

Moderna president Stephen Hoge knows investors are waiting to see the company grow in a big way and regain the momentum lost following outsized COVID-19 vaccine revenues.

Moderna’s stock tumbles after a disappointing outlook for revenue and the need to accelerate its cost-cutting plan.

Moderna Inc.’s third-quarter revenue fell by nearly a third and the pharmaceutical company cut its outlook, saying as part of its earnings report that supply constraints for its Covid-19 ...

(RTTNews) - Moderna, Inc. (MRNA) on Monday reaffirmed its previously issued revenue guidance from the sale of COVID-19 vaccine for the full year 2023.

Moderna Inc. shares moved lower Thursday, after the COVID vaccine maker posted far weaker-than-expected third-quarter earnings and lowered full-year sales guidance by up to $3 billion.